Population differences in breast cancer severity

Pharmacogenomics

Volumn 9, Issue 3, 2008, Pages 323-333

  Fejerman, Laura ^a   Ziv, Elad ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

African American women; Basal like tumor; Breast cancer; Environmental differences; Genetic difference; Hispanic women; Hormone receptor; Luminal tumor; Non Hispanic white women; Tumor subtype

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CASPASE 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOCHONDRIAL DNA; PROGESTERONE RECEPTOR; PROTEIN P53; TRANSFORMING GROWTH FACTOR;

AFRICAN AMERICAN; AMERICAN INDIAN; ASIAN; BREAST CANCER; BREAST FEEDING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE MUTATION; GENETIC DIFFERENCE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HISPANIC; HUMAN; MAMMOGRAPHY; PARITY; POPULATION RESEARCH; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SOCIAL STATUS; TUMOR GENE; TUMOR SUPPRESSOR GENE; BREAST TUMOR; ETHNIC GROUP; FEMALE; GENETICS; HOSPITALIZATION; INCIDENCE; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RACE; SURVIVAL;

BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HUMANS; INCIDENCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 42449130152     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.3.323     Document Type: Review

References (86)

1. Ries LAG, Eisner MP, Kosary CI et al.: SEER Cancer Statistics Review, 1975-2002. National Cancer Institute, Bethesda, MD, USA (2005),
2. Li CI, Malone KE, Daling JR: Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern. Med. 163(1), 49-56 (2003).
3. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50, 302 women with breast cancer and 93,973 women without the disease. Lancet 360(9328), 187-195 (2002).
4. Chlebowski RT, Hendrix SL, Langer RD et al.: Influence of estrogen plus progestin on breast cancer mammography in healthy postmenopausal women. The Women's Health Initiative randomized trial. JAMA 289, 3243-3253 (2003).
5. Gunzerath L, Faden V, Zakhari S, Warren K: National Institute on Alcohol Abuse and Alcoholism Report on moderate drinking. Alcohol. Clin. Exp. Res. 28 (6), 829-847 (2004).
6. Chlebowski RT, Chen Z, Anderson GL et al.: Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J. Natl Cancer Inst. 97 (6), 439-448 (2005).
7. Miller BA, Hankey BF, Thomas TL: Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am. J Epidemiol. 155(6), 534-545 (2002).
8. Gordon N: Association of education and income with estrogen receptor status in primary breast cancer. Am. J. Epidemiol. 142, 796-803 (1995).
9. Krieger N, van Den Eeden SK, Zava D et al.: Race/ethnicity, social class, and prevalences of breast cancer prognostic biomarkers: a study of white, black, and Asian women in the San Francisco Bay area. Ethn. Dis. 7, 137-149 (1997).
10. Smith-Bindman R, Miglioretti DL, Lurie N et al.: Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann. Intern. Med. 144, 541-553 (2006).
11. Berry DA, Cronin KA, Plevritis SK et al.: Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353, 1784-1792 (2005).
12. Wells BL, Horm JW: Stage at diagnosis in breast cancer: race and socioeconomic factors. Am. J. Public Health 82, 1383-1385 (1992).
13. Ward E, Jernal A, Cokkinides V et al.: Cancer disparities by race/ ethnicity and socioeconomic status. CA Cancer J. Clin. 54, 78-93 (2004).
14. Eidson M, Becker TM, Wiggins CL, Key CR, Samet JM: Breast cancer among Hispanics, American Indians and non-Hispanic Whites in New Mexico. Int. J. Epidem. 23(2), 231-237 (1994).
15. Newman LA, Mason J, Cote D et al.: African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer 94, 2844-2854 (2002).
16. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA.: Meta-analysis of survival in African American and White American Patients with breast cancer: ethnicity compared with socioeconomic status. J. Clin. Oncol. 24, 1342-1349 (2006).
17. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann. Intern. Med. 140, 184-188 (2004).
18. Pike MC, Kolonel LN, Henderson BE et al.: Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in Whites. Cancer Epidemiol. Biomarkers Prev. 11(9), 795-800 (2002).
19. Karliner LS, Napoles-Springer A, Kerlikowske K, Haas JS, Gregotich SE, Kaplan CP: Missed opportunities: family history and behavioral risk factors in breast cancer risk assessment among a multiethnic group of women. J. Gen. Intern. Med. 22(3), 308-314 (2007).
20. Kaplan CP Haas JS, Perez-Stable EJ et al.: Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol. Biomarkers Prev. 15(1), 162-166 (2006).
21. Vastag B: Breast cancer racial gap examined: no easy answers to explain disparities in survival. JAMA 290, 1838-1842 (2003).
22. O'Malley C, Le GM, Glaser SL, Shema SJ, West DW: Socioeconomic status and breast carcinoma survival in four racial/ethnic groups. A population-based study. Cancer 97, 1303-1311 (2003).
23. Weiss SE, Tartter PI, Ahmed S et al.: Ethnic differences in risk and prognostic factors for breast cancer. Cancer 76, 268-274 (1995).
24. Rosenberg J, Chia YL, Plevritis S: The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res. Treat. 89, 47-54 (2005).
25. Fregene A, Newman L: Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer 103, 1540-1550 (2005).
26. Millikan RC, Newman B, Tse C, Moorman PG, Conway K, Smith LV: Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat. (2007) (Epub ahead of print).
27. Carey LA, Perou C, Livasy CA et al.: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21), 2492-2502 (2006).
28. Cunningham JE, Butler WM: Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res. Treat. 88, 161-176 (2004).
29. Banerjee M, George J, Yee C, Hryniuk W, Schwartz K: Disentangling the effects of race on breast cancer treatment. Cancer (2007) (Epub ahead of print).
30. Muss HB, Hunter CP, Wesley M et al.: Treatment plans for black and white women with stage II node-positive breast cancer. Cancer 70, 2460-2467 (1992).
31. Michalski TA, Nattinger AB: The influence of black race and socioeconomic status on the use of breast-conserving surgery for Medicare beneficiaries. Cancer 79, 314-319 (1997).
32. Velanovich V, Yood MU, Bawle U et al.: Racial differences in the presentation and surgical management of breast cancer. Surgery 125, 375-379 (1999).
33. Bradley CJ, Given CW, Roberts C: Race, socioeconomic status, and breast cancer treatment and survival. J. Natl Cancer Inst. 94, 490-496 (2002).
34. Bickell NA, Wang JJ, Oluwole S et al.: Missed opportunities: racial disparities in adjuvant breast cancer treatment. J. Clin. Oncol. 24, 1357-1362 (2006).
35. Rouzier R, Perou CM, Symmans WF et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11(16), 5678-5685 (2005).
36. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumors. Nature 406(6797), 747-752 (2000).
37. Sorlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
38. Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003).
39. Hu Z, Fan C, Oh DS et al.: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).
40. Li CI, Malone KE, Daling JR: Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol. Biomarkers Prev. 11(7), 601-607 (2002).
41. Bauer KR, Brown M, Cress RD, Parise C, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 109, 1721-1728 (2007).
42. Elledge RM, Clark GM, Chamness GC, Osborne CK: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J. Natl Cancer Inst. 86(9), 705-712 (1994).
43. Ursin G, Ma H, Wu AH et al.: Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol. Biomarkers Prev. 12(4), 332-338 (2003).
44. Chen Z, Wu AH, Gauderman WJ et al.: Does mammographic density reflect ethnic differences in breast cancer incidence rates? Am. J. Epidemiol. 159(2), 140-147 (2004).
45. del Carmen MG, Halpern EF, Kopans DB et al.: Mammographic breast density and race. AJR Am. J. Roentgenol. 188(4), 1147-1150 (2007).
46. del Carmen MG, Hughes KS, Halpern E et al.: Racial differences in mammographic breast density. Cancer 98(3), 590-596 (2003).
47. Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K: Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol. Biomarkers Prev. 13(12), 2090-2095 (2004).
48. Couzin J: Probing the roots of race and cancer. Science 315, 592-594 (2007).
49. Freedman ML, Haiman CA, Patterson N et al.: Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. PNAS 103, 14068-14073 (2006).
50. Yeager M, Orr N, Hayes RB et al.: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39(5), 645-649 (2007).
51. Haiman CA, Patterson N, Freedman ML et al.: Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39(5), 638-644 (2007).
52. Gudmundsson J, Sulein P, Steinthorsdottir V et al.: Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against Type 2 diabetes. Nat. Genet. 39(8), 977-983 (2007).
53. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994).
54. Wooster R, Bignell G, Lancaster J et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995).
55. Olopade OL, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C: Breast cancer genetics in African Americans. Cancer 97(Suppl. 1), 236-245 (2003).
56. Pal T, Permuth-Wey J, Holtje T, Sutphen R: BRCA1 and BRCA2 mutations in a study of African-American breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 13(11), 1794-1799 (2004).
57. Haffty BG, Silber A, Matloff E, Chung J, Lannin D: Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African-American compared to white women. J. Med. Genet. 43, 133-137 (2006).
58. Nanda R, Schumm LP, Cummings S et al.: Genetic testing in an ethnically diverse cohort of high-risk women: a comparatic analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294, 1925-1933 (2005).
59. John, EM, Miron A, Gong G et al.: Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298, 2869-2876 (2007).
60. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS: Association between the T29→C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. JAMA 285, 2859-2863 (2001).
61. Dunning AM, Ellis PD, McBride S et al.: A transforming growth factorβ1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63, 2610-2615 (2003).
62. Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE: T29C polymorphism in the transforming growth factor β1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol. Biomarkers Prev. 13, 412-415 (2004).
63. Krippi P, Langsenlehner U, Renner W et al.: The L10P polymorphism of the transforming growth factor-β 1 gene is not associated with breast cancer risk. Cancer Lett. 201, 181-184 (2003).
64. Breast Cancer Association Consortium: Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J. Natl Cancer Inst. 98, 1382-1396 (2006).
65. Cox DG, Penney K, Guo Q. Hankinson SE. Hunter DJ: TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study. BMC Cancer 7(1), 175 (2007).
66. Sun T, Gao Y, Tan W et al.: A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat. Genet. 39(5), 605-613 (2007).
67. MacPherson G, Healey CS. Teare MD et al.: Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J. Natl Cancer Inst. 96, 1866-1869 (2004).
68. Frank B, Hemminki K. Wappenschmidt B et al.: Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis 27, 606-609 (2006).
69. Cox A, Dunning AM, Garcia-Closas M et al.: A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 39, 352-358 (2007).
70. Frank B, Rigas SH, Bermejo JL et al.: The CASP8-652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res. Treat. (2007) (Epub ahead of print).
71. Canter JA, Kallianpur AR, Parl F, Millikan RC: Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 65(17), 8028-8033 (2005).
72. Ziv E, Burchard EG: Human population structure and genetic association studies. Pharmacogenomics 4, 431-441 (2003).
73. Freedman ML, Reich D, Penney KL: Assessing the impact of population stratification on genetic association studies. Nat. Genet. 36, 388-393 (2004).
74. Easton DF, Pooley KA, Dunning AM et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148), 1087-1093 (2007).
75. Hunter DJ, Kraft P, Jacobs KB et al.: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39(7), 870-874 (2007).
76. Stacey SN, Manolescu A, Sulem P et al.: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39(7), 865-869 (2007).
77. Murabito JM, Rosenberg CL, Finger D et al.: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med. Genet. 8(Suppl. 1), S6 (2007).
78. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA; SEARCH Investigators: Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet. 3(3), E42 (2007).
79. Jones BA, Kasi SV, Howe CL et al.: African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101(6), 1293-1301 (2004).
80. Thor AD, Moore DH, Edgerton SM et al.: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst. 84(11), 845-855 (1992).
81. Salonen JT, Uimari P, Aalto JM et al.: Type 2 diabetes whole-genome association study in four populations: the DiaGen consortium. Am. J. Hum. Genet. 81(2), 338-345 (2007).
82. Scott LJ, Mohlke KL, Bonnycastle LL et al.: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316(5829), 1341-1345 (2007).
83. Scuteri A, Sanna S, Chen WM: Genomewide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 3(7), E115 (2007).
84. Wellcome Trust Case Control Consortium: Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. (2007) (Epub ahead of print).
85. Frayling TM, Timpson NJ, Weedon MN et al.: A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316(5826), 889-894 (2007).
86. Nyagol J, Nyong'o A, Byakika B et al.: Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. Anal. Quant. Cytol. Histol. 28(2), 97-103 (2006).